Patients Wary of Governments, Companies Pushing AI as a Rural Healthcare Solution - KFF Health News
Reported by KFF Health News · all stories from kffhealthnews.org
Editorial digest
A report indicates that individuals in rural areas harbor skepticism about artificial intelligence being promoted by public and private entities for their healthcare needs. Their concerns center on the reliability and impact of these technologies.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at KFF Health News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom11/12/2026
STAT+: New documents raise more questions about Medicare’s AI prior-authorization experiment
Newly surfaced records prompt growing scrutiny regarding Medicare's pilot initiative using artificial intelligence for coverage approvals.
- Trusted health newsroom11/6/2026
STAT+: After Medicare punts RPM overhaul to 2029, advocates see window to fight back
Advocates plan to challenge Medicare's remote monitoring overhaul after officials postponed the policy update to 2029.
- Trusted health newsroom11/5/2026
STAT+: Medicare delays controversial remote patient monitoring rule to 2029
Federal regulators have postponed a contentious Medicare remote patient monitoring policy update until 2029.
- Trusted health newsroom11/5/2026
STAT+: What the midterms could mean for the future of health AI
Upcoming midterm election outcomes could reshape regulatory policies and federal oversight for medical artificial intelligence technologies.
- Trusted health newsroom11/3/2026
STAT+: FDA, CMS look to collaborate with states on health AI
Federal regulators at the FDA and CMS plan to partner with state authorities regarding medical artificial intelligence.
- Trusted health newsroom10/30/2026
STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Federal health agencies are working quickly to prevent oversight bottlenecks as states prepare clinical artificial intelligence trials.
